Literature DB >> 32048692

The affinity of RSK for cylitol analogues of SL0101 is critically dependent on the B-ring C-4'-hydroxy.

Yu Li1, Pedro Seber2, Eric B Wright3, Sharia Yasmin4, Deborah A Lannigan5, George A O'Doherty1.   

Abstract

Five cyclitol analogues of SL0101 with variable substitution at the C-4' position (i.e., OH, Cl, F, H, OMe) were synthesized. The series of analogues were evaluated for their ability to inhibit p90 ribosomal S6 kinase (RSK) activity. The study demonstrated the importance of the B-ring C-4' hydroxy group for RSK1/2 inhibition.

Entities:  

Year:  2020        PMID： 32048692      PMCID： PMC7285658          DOI： 10.1039/d0cc00128g

Source DB:  PubMed          Journal:  Chem Commun (Camb)        ISSN： 1359-7345            Impact factor:   6.222


  26 in total

1.  De novo asymmetric synthesis of the mezzettiaside family of natural products via the iterative use of a dual B-/Pd-catalyzed glycosylation.

Authors:  Sumit O Bajaj; Ehesan U Sharif; Novruz G Akhmedov; George A O'Doherty
Journal:  Chem Sci       Date:  2014-06       Impact factor: 9.825

2.  Synthesis of a potent and selective inhibitor of p90 Rsk.

Authors:  David J Maloney; Sidney M Hecht
Journal:  Org Lett       Date:  2005-03-17       Impact factor: 6.005

3.  Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation.

Authors:  Jeffrey A Smith; Celeste E Poteet-Smith; Yaming Xu; Timothy M Errington; Sidney M Hecht; Deborah A Lannigan
Journal:  Cancer Res       Date:  2005-02-01       Impact factor: 12.701

4.  Total synthesis of jadomycin A and a carbasugar analogue of jadomycin B.

Authors:  Mingde Shan; Ehesan U Sharif; George A O'Doherty
Journal:  Angew Chem Int Ed Engl       Date:  2010-12-03       Impact factor: 15.336

5.  RSK1 drives p27Kip1 phosphorylation at T198 to promote RhoA inhibition and increase cell motility.

Authors:  Michelle D Larrea; Feng Hong; Seth A Wander; Thiago G da Silva; David Helfman; Deborah Lannigan; Jeffrey A Smith; Joyce M Slingerland
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-22       Impact factor: 11.205

Review 6.  Ribosomal S6 kinase (RSK) modulators: a patent review.

Authors:  Katarzyna A Ludwik; Deborah A Lannigan
Journal:  Expert Opin Ther Pat       Date:  2016-08-01       Impact factor: 6.674

7.  Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer.

Authors:  Katarzyna A Ludwik; J Preston Campbell; Mingzong Li; Yu Li; Zachary M Sandusky; Lejla Pasic; Miranda E Sowder; David R Brenin; Jennifer A Pietenpol; George A O'Doherty; Deborah A Lannigan
Journal:  Mol Cancer Ther       Date:  2016-08-15       Impact factor: 6.261

8.  Epidermal growth factor (EGF) regulates α5β1 integrin activation state in human cancer cell lines through the p90RSK-dependent phosphorylation of filamin A.

Authors:  Daniel Vial; Paula J McKeown-Longo
Journal:  J Biol Chem       Date:  2012-09-24       Impact factor: 5.157

9.  Synthesis of carbasugar C-1 phosphates via Pd-catalyzed cyclopropanol ring opening.

Authors:  Mingde Shan; George A O'Doherty
Journal:  Org Lett       Date:  2008-07-18       Impact factor: 6.005

10.  RSK2 protein suppresses integrin activation and fibronectin matrix assembly and promotes cell migration.

Authors:  Joanna E Gawecka; Shirley S Young-Robbins; Florian J Sulzmaier; Maisel J Caliva; Minna M Heikkilä; Michelle L Matter; Joe W Ramos
Journal:  J Biol Chem       Date:  2012-11-01       Impact factor: 5.157
View more
  1 in total

1.  Synthesis and Biological Evaluation of 4'-Substituted Kaempfer-3-ols.

Authors:  Sugyeom Kim; Yu Li; Lin Lin; Peyton R Sayasith; Ariel T Tarr; Eric B Wright; Sharia Yasmin; Deborah A Lannigan; George A O'Doherty
Journal:  J Org Chem       Date:  2020-02-27       Impact factor: 4.354
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.